762 / 1096
S746
ESTRO 36
_______________________________________________________________________________________________
7.27 ± 1.07 months (p = 0.000). The primary diagnosis:
lung 6.96 ± 1.34 months, breast 5.38 ± 1.47 months,
colorectal 5.72 ± 2.19 months (p = 0.016). The histology:
adenocarcinoma 7.93 ± 1.99 months, infiltrating ductal
5.36 ± 1.47 months, small cell 4.94 ± 1.07 months, and
epidermoid 3.08 ± 1.0 months, (p = 0.004). In patients with
breast cancer estrogen and progesterona receptors,
negative 1.54 ± 1.3 months and positive 9.8 ± 1.03 months
(p=0.025).
Conclusion
In patients with brain metastases, the best prognosis are
lung cancer, adenocarcinoma, ECOG 0, and in breast
cancer are positive estrogen and progesterona receptors.
EP-1394 Prognostic factor for palliative radiotherapy of
bone metastases in good performance-status patients
Y. Hamamoto
1
, S. Taguchi
2
, T. Manabe
2
, H. Kanzaki
1
, K.
Nagasaki
1
, N. Takata
1
, T. Mochizuki
1
1
Ehime University, Radiology, Toon-city, Japan
2
Saiseikai Imabari Hospital, Radiology, Imabari-city,
Japan
Purpose or Objective
Performance status is well-known prognostic factor for
patients received palliative care. Regarding patients with
good performance status, prognostic factors after
palliative intent radiation therapy (PIRT) were
investigated.
Material and Methods
Between Dec. 2009 and Mar. 2014, 148 patients received
initial PIRT in our institution. Of these, 100 patients were
able to be followed up until death or for more than six
months. Among these 100 patients, 63 patients (age, 58-
89, median 69; male/female=45/18) were in good
performance status (PS 0-1), and were reviewed in this
study. Survival time was calculated from the initiation of
initial PIRT. Assessed factors were age (<75 vs. >75), sex,
primary sites (breast vs. other organs), sites of initial PIRT
(bone/soft-tissue/lymph-nodes vs. other organs), and
administration of chemotherapy before PIRT (yes vs. no).
Univariate analysis was performed by log-rank test and
multivariate analysis was performed by Cox proportional
hazard model.
Results
Regarding all 63 patients, median survival time was seven
months and the 1-year overall survival rate was 34%. On
univariate analysis, irradiate sites was the only
statistically significant factor for survival after PIRT
(p=0.0159). Irradiate sites was the statistically significant
factor also on multivariate analysis (p=0.0179). The 1-year
overall survival rate of the patients who received PIRT to
bone/soft-tissue/lymph-nodes was 46% (median survival
time, 11 months), while that was 15% for the patients who
received PRIT to other organs (median survival time, 4
months).
Conclusion
With regard to patients with good performance status,
prognosis of patients who received PIRT to bone/soft-
tissue or lymph-nodes was comparatively good. Despite
small patient number of this study, it seemed that
extremely hypofractionated PIRT was not suitable for
these patients.
EP-1395 CyberKnife treatment of intraorbital
metastases: a single center experience on 24 lesions.
G. Riva
1
, M. Augugliaro
1
, G. Piperno
1
, A. Ferrari
1
, E.
Rondi
1
, S. Vigorito
1
, R. Orecchia
1
, B.A. Jereczek-Fossa
1
1
Istituto Europeo di Oncologia - IEO, Radiotherapy, MIlan,
Italy
Purpose or Objective
The aim of the study is to evaluate the feasibility, acute
toxicity and symptoms control of CyberKnife (Accuray,
Sunnyvale, CA)-based stereotactic radiotherapy (CBK-SRT)
on intraorbital metastases.
Material and Methods
This retrospective analysis included patients (pts) with
symptomatic metastases located wholly within the orbit.
Palliative radiation treatment was performed using
CyberKnife image-guided technology (using skull-tracking
technique). Gross tumor volume (GTV) volume was
defined on a pre-radiotherapy magnetic resonance
imaging (MRI) with Gadolinium. Treated volumes and
dose-volume histograms (DVHs) are discussed. Acute
toxicity was recorded according to Radiation Therapy
Oncology Group/European Organization for Research and
Treatment of Cancer (RTOG/EORTC) Scale.
Results
Between April 2012 and July 2016, 24 metastases (21 pts,
3 treated bilaterally) underwent CBK-SRT for intraorbital
lesions (10 intraocular, 14 periocular) from different
primary tumors (breast in 13 pts, lung in 3 pts, kidney in 2
pts, lymphoma in 1 pts, thyroid in 1 pts, trunk
leiomyosarcoma in
1
pts).
The median treatment dose was 18 Gy (range, 15-24 Gy)
given over a median of 3 fractions (range, 2-3 fractions)
with a median dose of 6 Gy per fraction (range, 5-10
Gy/fraction). Treated volumes and DVHs are reported in
Table 1.
At the end of the treatment, grade 1 toxicity according to
RTOG/EORTC score was observed in 8 cases. No change in
visual field or loss of vision was documented.
13 lesions of 24 had undergone post-radiotherapy MRI and
after median follow-up of 6 months (range, 2.0-26.5
months) no local recurrence occurred. All of these
patients reported decreasing pre-radiotherapy symptoms
and improvement in quality of life. Longer follow-up
(more than 12 months) is available in 4 lesions with
complete radiological response in all cases.
Conclusion
In our experience, CyberKnife radiotherapy is a well-
tolerated, safe and efficacious technique for palliative
treatment of intraocular and periocular metastases.